Navigation Links
Vermillion's Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
Date:5/1/2008

nd uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize its PAD diagnostics products in 2008 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and commercialize PAD diagnostic products based on findings from its disease association studies; (3) unproven ability of Vermillion to discover or identify new protein biomarkers and use such information to develop PAD diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its PAD diagnostic products; (5) uncertainty of market acceptance of its PAD diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; and (6) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisio
'/>"/>
SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
2. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. VNUS Medical Technologies to Report Third-Quarter 2007 Results and Webcast Teleconference on October 29
5. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
6. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
7. WorldHeart Schedules Teleconference
8. VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7
9. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
10. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
11. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... TX (PRWEB) January 15, 2014 More ... disease, and about 1 in 3 seniors will die ... source ). These jaw-dropping figures have shocked many Americans ... and, hopefully, help prevent these tragic age-related cognitive disorders. ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... (NYSE: CVD ) today reported GAAP earnings ... $0.35 per diluted share.  Included in fourth quarter results ... $0.10 of which relates to the completion of the ... the termination of a research products inventory supply agreement ...
... at the University of California, Riverside has identified a property ... to finding the Higgs boson in particle physics. Graphene, ... carbon atoms arranged in a hexagonal lattice. Because of ... themselves well to stacking. BLG is formed ...
... 2012 SPO Medical Inc. ( SPOM ... for use in portable monitoring devices, announced today an ... revenue generation strategy for fiscal 2012 primarily based on ... range of consumer wellness devices. SPO currently ...
Cached Biology Technology:Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 2Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 3Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 4Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 5Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 6Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 7Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 8Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 9Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 10Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 11Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 12Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 13Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 14Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 15Bilayer graphene works as an insulator 2Bilayer graphene works as an insulator 3SPO Updates Shareholders on 2012 Corporate Strategy 2SPO Updates Shareholders on 2012 Corporate Strategy 3
(Date:7/9/2014)... increasing concern about the prevalence of antibiotic-resistant illness, ... new pathway to disabling disease: blocking bacteria,s access ... showed how bacterial siderophore, a small molecule, captures ... bacterial growth as well as how the ... process. Their findings appear in a recent edition ...
(Date:7/9/2014)... some shark species may be able to cope with the ... temperatures. , The Arctic today is best known for its ... that. Roughly 53 to 38 million years ago during what ... similar to a huge temperate forest with brackish water, home ... hippo-like creatures, crocodiles and giant tortoises. Much of what is ...
(Date:7/9/2014)... but often can be defeated with antibiotics and then ... Now, scientists have built a new weapon against such pathogens ... journal ACS Applied Materials & Interfaces , their study ... them than medicine alone. , David Leong, Jianping Xie and ... undetectable in the human body or in places that antibiotics ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... 2010) BioSpace and BioMed Central are announcing ... today, a new online community for life science ... news. The new Career Network combines ... access publisher BioMed Central,s 1.2 million registrants to ...
... Girls in homes without a biological father are more ... a new study led by researchers at the University of ... to be published Sept. 17 in the Journal of ... related father in the home predicted earlier breast and pubic ...
... in environments ranging from the rainforests of the Amazon to ... this diversity would not be possible if the ancestors of ... green algal cousins. Moving onto dry land required major lifestyle ... turn helped change global climate and atmospheric conditions to conditions ...
Cached Biology News:Father absence linked to earlier puberty among certain girls 2Father absence linked to earlier puberty among certain girls 3Father absence linked to earlier puberty among certain girls 4Learning to live on land: How some early plants overcame an evolutionary hurdle 2
... priced, full ring small animal imaging PET ... microPET R4 low retail price, it outperfoms ... count rate performance, energy resolution, timing resolution, ... small animal PET (Positron Emission Tomography) imaging ...
... EVO series offers versatile liquid handling platforms ... a wide variety of life science applications.The ... base sizes (75, 100, 150 and 200 ... a platform that will advance with their ...
...
... microPET 220 utilizes utilizies CTI Molecular ... to superior resolution, sensitivty, and a ... user the flexibility to image multiple ... quality., microPET is a dedicated small ...
Biology Products: